Ryan Cohlhepp
CEO, COO at Bicara Therapeutics Inc. (BCAX); COO, President at Bicara Therapeutics Inc. (BCAX)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $4.6M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Sep 10SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 14,058185,083 held (−7%) | $22.77 | $320K | -23.1% |
| Sep 10SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 3,442181,641 held (−2%) | $23.43 | $81K | -25.3% |
| Aug 12SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 18,750181,641 held (−9%) | $27.98 | $525K | -37.5% |
| Jul 10SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 22,833187,558 held (−11%) | $28.76 | $657K | -39.2% |
| Jul 10SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 4,306183,252 held (−2%) | $29.80 | $128K | -41.3% |
| Jul 10SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 1,075182,177 held (−1%) | $30.35 | $33K | -42.3% |
| Jul 10SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 536181,641 held (−0%) | $29.00 | $16K | -39.7% |
| May 18SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 8,000196,141 held (−4%) | $20.29 | $162K | -13.8% |
| May 18SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 4,500191,641 held (−2%) | $20.29 | $91K | -13.8% |
| Apr 17SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 8,000200,641 held (−4%) | $23.01 | $184K | -23.9% |
| Apr 17SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 4,500196,141 held (−2%) | $23.01 | $104K | -23.9% |
| Mar 17SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 8,000205,141 held (−4%) | $19.66 | $157K | -11.0% |
| Mar 17SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 4,500200,641 held (−2%) | $19.66 | $88K | -11.0% |
| Mar 5SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 12,892209,641 held (−6%) | $18.16 | $234K | -3.6% |
| Mar 5SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 4,500205,141 held (−2%) | $18.16 | $82K | -3.6% |
| Feb 27SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 3,108210,164 held (−1%) | $18.04 | $56K | -3.0% |
| Feb 27SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 523209,641 held (−0%) | $18.04 | $9K | -3.0% |
| Jan 26SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 3,828210,164 held (−2%) | $18.10 | $69K | -3.3% |
| Jan 20SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 149213,992 held (−0%) | $18.02 | $3K | -2.9% |
| Dec 16SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 8,000193,641 held (−4%) | $18.68 | $149K | -6.3% |
| Dec 16SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 4,500189,141 held (−2%) | $18.68 | $84K | -6.3% |
| Nov 25SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 8,000198,141 held (−4%) | $18.05 | $144K | -3.0% |
| Nov 25SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 4,500193,641 held (−2%) | $18.05 | $81K | -3.0% |
| Oct 16SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 8,000202,641 held (−4%) | $18.16 | $145K | -3.6% |
| Oct 16SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 4,500198,141 held (−2%) | $18.16 | $82K | -3.6% |
| Oct 8SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 24,000221,141 held (−10%) | $18.06 | $433K | -3.1% |
| Oct 8SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 15,600205,541 held (−7%) | $18.06 | $282K | -3.1% |
| Oct 8SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 8,000205,541 held (−4%) | $18.06 | $144K | -3.1% |
| Oct 8SEC | BCAXBicara Therapeutics Inc. | Sell Plan | 2,900202,641 held (−1%) | $18.06 | $52K | -3.1% |
- Sell
CEO, COO Ryan Cohlhepp sold $320K of BCAX at $22.77 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, COO Ryan Cohlhepp sold $81K of BCAX at $23.43 — pre-scheduled 10b5-1 plan sale.
- Sell
COO, President Ryan Cohlhepp sold $525K of BCAX at $27.98 — pre-scheduled 10b5-1 plan sale.
- Sell
COO, President Ryan Cohlhepp sold $657K of BCAX at $28.76 — pre-scheduled 10b5-1 plan sale.
- Sell
COO, President Ryan Cohlhepp sold $128K of BCAX at $29.80 — pre-scheduled 10b5-1 plan sale.
- Sell
COO, President Ryan Cohlhepp sold $33K of BCAX at $30.35 — pre-scheduled 10b5-1 plan sale.